Primary refractory Hodgkin's disease

Annals of Oncology

Volumn 9, Issue SUPPL. 5, 1998, Pages

  Horning, S J ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autologous transplantation; Hodgkin's disease; Induction failure; Primary refractory; Salvage chemotherapy; Salvage radiotherapy; Transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; ARABINOSIDE; BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINCRISTINE; VINCRISTINE SULFATE;

AUTOTRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONFERENCE PAPER; HODGKIN DISEASE; HUMAN; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT FAILURE;

EID: 0032448433     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/9.suppl_5.S97     Document Type: Conference Paper

References (5)

1. DeVita VT Jr, Simon RM, Hubbard SM et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92: 587-95.
2. Bonfante V, Santoro A, Viviani S et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15: 528-34.
3. Connors JM, Klimo P, Adams G et al. Treatment of advanced Hodgkin's disease with chemotherapy - comparison of MOPP/ ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada clinical trials group [published erratum appears in J Clin Oncol 1997; 15: 2762]. J Clin Oncol 1997; 15: 1638-45.
4. Raemaekers J, Burgers M, Henry-Amar M et al. Patients with stage III-IV Hodgkin's disease in partial remission after MOPP/ ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: Interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie. Ann Oncol 1997; 8 (Suppl 1): 111-4.
5. Click JH, Young ML, Harrington D et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The eight-year results of the intergroup trial. J Clin Oncol 1998; 16: 19-26.